Follow
Flaherty K
Flaherty K
Massachusetts General Hospital, University of Pennsylvania
Verified email at mgh.harvard.edu
Title
Cited by
Cited by
Year
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
90232011
Final version of 2009 AJCC melanoma staging and classification
CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ...
Journal of clinical oncology 27 (36), 6199, 2009
55292009
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
42402010
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ...
Science 352 (6282), 189-196, 2016
37882016
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ...
New England Journal of Medicine 367 (18), 1694-1703, 2012
30742012
Improved overall survival in melanoma with combined dabrafenib and trametinib
C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ...
New England Journal of Medicine 372 (1), 30-39, 2015
28662015
Genomic classification of cutaneous melanoma
R Akbani, KC Akdemir, BA Aksoy, M Albert, A Ally, SB Amin, H Arachchi, ...
Cell 161 (7), 1681-1696, 2015
26302015
Improved survival with MEK inhibition in BRAF-mutated melanoma
KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ...
New England Journal of Medicine 367 (2), 107-114, 2012
25622012
Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib
JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ...
New England Journal of Medicine 366 (8), 707-714, 2012
25522012
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
21902017
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
20002010
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
19562014
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ...
Nature 487 (7408), 500-504, 2012
19372012
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ...
Nature 468 (7326), 968-972, 2010
17112010
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E)
PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ...
Nature 480 (7377), 387-390, 2011
16202011
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
15192015
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ...
Cell 175 (4), 998-1013. e20, 2018
13412018
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ...
Journal of Clinical Oncology 24 (16), 2505-2512, 2006
13062006
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ...
Science 357 (6356), 1156-1160, 2017
12822017
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
11912014
The system can't perform the operation now. Try again later.
Articles 1–20